Research Article

Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients

Table 6

Nonparametric analysis of survival for L-sarcoma and non-L-sarcoma patients, univariate Kaplan–Meier analysis with median survival in months and logrank test, and multivariate Cox regression. The univariate hazard ratio for age per year increase was 0.99 for all tests.

Nonparametric survivalL-SarcomaNon-L-sarcoma
Univariate Kaplan–MeierMedian PFS95% CI valueMedian PFS95% CI value

Progression-free survival
Age0.96–1.020.3950.97–1.010.460
Sex
(i) Female3.190.00–6.620.6212.891.76–4.030.931
(ii) Male4.572.43–6.712.300.81–3.80
ECOG PS
(i) 03.681.08–6.280.6023.220.00–6.450.022
(ii) 1 + 23.290.00–7.901.910.46–3.35
Drug received
(i) Trabectedin5.193.31–7.070.0742.041.52–2.550.819
(ii) Ifosfamide2.630.43–4.833.252.33–4.18
Disease status
(i) Local3.290.00–7.010.7403.250.00–6.800.875
(ii) Metastatic3.941.40–6.482.431.27–4.30
Multivariate Cox regressionHR95% CI valueHR95% CI value
(i) Drug received0.600.33–1.070.0861.350.67–2.740.403
(ii) ECOG PS1.110.63–1.950.7152.431.16–5.070.018

Univariate Kaplan–MeierMedian OS95% CI valueMedian OS95% CI value

Overall survival
Age0.96–1.020.4980.97–1.010.273
Sex
(i) Female8.352.66–14.00.0719.175.63–12.70.796
(ii) Male14.8510.2–19.55.553.68–7.42
ECOG PS
(i) 013.417.57–19.20.03313.777.72–19.80.008
(ii) 1 + 28.353.92–12.85.233.64–6.81
Drug received
(i) Trabectedin11.807.78–15.80.1845.980.70–11.30.903
(ii) Ifosfamide8.220.00–21.28.945.97–11.9
Disease status
(i) Local7.432.82–12.00.66611.806.30–17.30.594
(ii) Metastatic13.417.85–19.06.972.81–11.1
Multivariate Cox regressionHR95% CI valueHR95% CI value
(i) Drug received0.660.37–1.180.1621.730.85–3.500.128
(ii) ECOG PS1.911.06–3.450.0322.991.44–6.200.003

PFS: progression-free survival; OS: overall survival; 95% CI: 95% confidence interval; ECOG PS: ECOG performance score; HR: hazard ratio.